CAR-T cell therapy is a form of combined gene and cell therapy that has revolutionized cancer treatment. Remarkable efficacy and manageable safety profile have been observed by several FDA-approved cell therapy products against blood cancers, including cilta-cel, an autologous CAR-T cell therapy that targets BCMA. Cilta-cel is a structurally differentiated CAR-T cell therapy containing a 4-1BB (CD137) co-stimulatory domain and 2 BCMA-targeting single-domain antibodies designed to confer avidity. The unprecedented clinical response suggests that cilta-cel has the potential to become the best-in-class BCMA-targeted CAR-T cell therapy for the treatment of MM. With the success of cilta-cel, we have built fully-integrated in-house R&D capacities encompassing drug discovery, pre-clinical studies, translational research, manufacture, and clinical development to efficiently generate and advance a broad portfolio of Phase 1 and earlier stage product candidates targeting various solid and hematologic tumor types that address significant unmet needs among patients. Key components of our research and development capacities include in-house antibody discovery, CAR design and screening, innovative disease-tailored armors, multiple allogeneic platforms, robust CMC manufacture and global clinical development. In this presentation, I will share our integrated R&D capacities and highlight several of our autologous cell therapy assets, LB1908, LB2101, and LB2102 to illustrate our recent progress in targeting solid tumors.

• Review current progress in CAR-T cell therapy approaches against hematological malignancies, including efficacy and adverse events.
• Discuss Cilta-cel as a novel B-cell maturation antigen (BCMA)-targeting autologous CAR T-cell therapy for patients with relapsed/refractory multiple myeloma and unique structural design.
• Indicate the current limitations of CAR-T cell therapies in solid tumors and strategies that circumvent their challenging landscape.